WallStSmart
REVB

Revelation Biosciences Inc

NASDAQ: REVB · HEALTHCARE · BIOTECHNOLOGY

$1.04
-6.16% today

Updated 2026-06-05

Market cap
$3.99M
P/E ratio
P/S ratio
2.88x
EPS (TTM)
$-1.32
Dividend yield
52W range
$1 – $13
Volume
0.1M

Revelation Biosciences Inc (REVB) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201420152016201720182019202020212022202320242025
Revenue$21.07M$27.66M$48.81M$74.00M$85.11M$95.81M$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)+31.3%+76.5%+51.6%+15.0%+12.6%-100.0%
Cost of revenue$0.00$0.00$0.00$0.00$0.00$69166.00$40008.00$25049.00$27923.00$27058.00
Gross profit$21.07M$27.66M$45.25M$70.82M$80.98M$90.91M$-69166.00$-40008.00$-25049.00$-27923.00$-27058.00
Gross margin100.0%100.0%92.7%95.7%95.1%94.9%
R&D$2561.00$6.91M$5.38M$4.15M$3.55M$4.06M
SG&A$23.98M$21.49M$31.29M$33.98M$36.34M$145492.00$5.04M$5.49M$4.51M$4.43M$5.01M
Operating income$7.45M$10.28M$18.76M$32.69M$38.89M$-3638.00$-145492.00$-11.95M$-10.86M$-8.66M$-7.98M$-9.07M
Operating margin35.3%37.2%38.4%44.2%45.7%-0.0%
EBITDA$-3638.00$-145492.00$-11.93M$-10.84M$-8.63M$-7.95M$-9.04M
EBITDA margin0.0%0.0%0.0%0.0%0.0%-0.0%
EBIT$0.00$0.00$0.00$0.00$0.00$-175500.00$-145492.00$-11.95M$-10.86M$-8.66M$-7.98M$-9.07M
Interest expense$0.00$0.00$0.00$0.00$0.00$0.00$0.00$41759.00$34962.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$4.50M$6.20M$8.78M$16.27M$27.63M$-3638.00$-136408.00$-11.99M$-10.83M$-120254.00$-15.04M$-8.91M
Net income growth (YoY)+37.7%+41.5%+85.4%+69.8%-100.0%-3649.5%-8687.5%+9.7%+98.9%-12405.6%+40.7%
Profit margin21.4%22.4%18.0%22.0%32.5%-0.0%

Frequently asked questions

How much free cash flow does REVB generate?

REVB produced $-8.27M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is REVB's balance sheet healthy?

REVB holds $10.70M in cash and equivalents against — in long-term debt, on $8.86M of shareholder equity. That debt is best read against the cash flow the business throws off each year.